Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV
Authors:
- 1 March 2019
- journal article
- conference paper
- Published by SAGE Publications in AIDS Patient Care and STDs
- Vol. 33 (3) , 104-111
Abstract
To better understand acceptability of long-acting injectable antiretroviral treatment (LAI-ART) regimens for HIV management, we conducted seven semi-structured focus group discussions with experienced HIV care providers and persons living with HIV (PLWH) and five individual interviews with parents of children living with HIV in the western United States. Although providers were wary about a potential negative impact on consistent engagement in care, they predicted that patients, especially those with adherence challenges, would be enthusiastic about LAI options. Many PLWH, especially young adults, welcomed the option of an LAI-ART regimen; however, others feared injections and expressed concerns about possible side effects, dosing more frequent than every 2 weeks, additional costs, and lower efficacy. Parents' interest varied according to their child's age and sensitivity to injections. In summary, potential users considered LAI-ART generally acceptable yet voiced possible concerns as well, especially if their current pill-based regimen was effective in achieving viral suppression.Keywords
This publication has 20 references indexed in Scilit:
- Antiretroviral implants for treatment and prevention of HIV infectionCurrent Opinion in HIV and AIDS, 2018
- Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trialThe Lancet Global Health, 2018
- Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment—Clinical Points of View and Practical ConsiderationsFrontiers in Pharmacology, 2017
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialThe Lancet, 2017
- Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapyAdvanced Drug Delivery Reviews, 2016
- Implementation challenges for long-acting antivirals as treatmentCurrent Opinion in HIV and AIDS, 2015
- Long-acting HIV drugs advanced to overcome adherence challengeNature Medicine, 2014
- The population effectiveness of highly active antiretroviral therapy: Are good drugs good enough?Current HIV/AIDS Reports, 2005
- Three Approaches to Qualitative Content AnalysisQualitative Health Research, 2005
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997